Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Khoan VuChi-Heng WuChen-Yen YangAaron ZhanErika CavalloneWade BerryPamela HeeterLaura PincusMatthew J WieduwiltBasem M WilliamCharalambos AndreadisLawrence K KaplanFrank McCormickPierluigi PorcuJonathan E BrammerWeiyun Z AiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Romidepsin plus LD demonstrated an acceptable safety profile and promising clinical efficacy with deep skin responses in relapsed/refractory CTCL. Thus, this combination could be considered as a bridge to skin-directed treatment or allogeneic hematopoietic cell transplantation in patients with aggressive CTCL.